Pharmaceutical Antitrust in Italy: 32 Answers

By Martino Sforza on September 19, 2016

Posted In Healthcare Antitrust, Italian Developments

This article, published in Getting the Deal Through, reviews the legislation that creates the pharmaceutical regulation framework in Italy, particularly with regard to mergers and acquisitions, anticompetitive conduct, product development and licensing agreements, and marketing agreements.

Read the full article.

Tags: AIFA, anticompetitive exchanges of information, antitrust violation, Community Code Relating to Medicinal Products for Human Use, competition law, EU, Generic drugs, Italian Medicines Agency, marketing authorization, Ministry of Economic Development, Ministry of Health, Ministry of the Economy and Finance, National Health Service, pharmaceutical product pricing, technology transfer agreements, TFEU, Treaty on the Functioning of the European Union, TTBER

Martino Sforza
Martino Sforza focuses his practice on advising European and international clients before the European Commission, the national competition and regulatory authorities, and the civil and administrative courts. He has extensive experience in assisting international clients on antitrust, distribution, consumer protection, data privacy rules and issues related to regulated markets.

Pharmaceutical Antitrust in Italy: 32 Answers

Related Posts

BLOG EDITORS

STAY CONNECTED

TOPICS

ARCHIVES

RECENT POSTS